Abstract
Despite the recent decline, neonatal mortality rates (NMR) remain high in India. Family members are often responsible for the postpartum care of newborns and mothers. Yet, low health literacy and varied beliefs can lead to poor neonatal health outcomes. Postpartum education for family caregivers can improve the adoption of evidence-based newborn care and health outcomes. The Care Companion Program (CCP) is a hospital-based, pre-discharge health training session where nurses teach key healthy behaviors and help mothers and family members learn skills and practice in the hospital. Here, we assessed the impact of CCP on NMR. We conducted a quasi-experimental study to assess the effect of the CCP sessions on mortality outcomes among families seeking care in 28 public tertiary facilities, across 4 Indian states. Neonatal mortality outcomes were reported post-discharge, collected via phone surveys at four weeks of age of baby, between October 2018 to February 2020. Risk ratios (RR), adjusting for hospital-level clustering, were calculated by comparing mortality rates before and after CCP implementation. A total of 46,428 families participated in the pre-intervention group and 87,305 in the post-intervention group; 76% of families participated in the phone survey. The crude NMR was 33.64 deaths per 1000 live births (RR=0.82, 95% CI: 0.76, 0.87). After accounting for hospital-clustering, the NMR was 41.3 (adjusted RR=0.81, 95% CI: 0.71, 0.93). There may be a substantial benefit to family-centered education in the early postnatal period to reduce neonatal mortality.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Ariadne Labs staff was funded by a grant from Noora Health for this work. Noora Health is supported by private philanthropic donors, foundations, and corporate giving. Aurora Health Innovations LLP is a client of Noora Health. Aurora Health Innovations was remunerated by Noora Health for research related services rendered towards completion of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approval for primary data collection was obtained from the ACE independent Ethics Committee (DCGI Reg. No. ECR/141/Indt/KA/2013/RR-19 NABH Certificate No.EC-CT-2018-0029) and SPECT. The primary data with identifier details rested with the core team in India. The deidentified data was shared with collaborators for analysis. For this secondary analysis (DCGI Reg. No. ECR/141/Indt/KA/2013), Harvard University Institutional Review Board (Protocol # IRB19-1140) deemed the study exempt
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
Complete data will be available upon request
